WCBS’ CEO Radio Features Isoray CEO Lori Woods

WCBS’ CEO Radio Features Isoray CEO Lori Woods

In the first of a five part series, WCBS’s CEO Radio talks to CEO Lori Woods about how the company moved quickly to meet the challenges of COVID-19 assuring doctors and their patients access to cancer fighting Cesium-131 internal radiation therapy. News-talk radio...

CEO Lori Woods discusses the impact of Cesium-131 with Big Biz TV

In a recent conversation with Big Biz TV, CEO Lori Woods talked with Big Biz TV about Isoray’s important role in the war on cancer and the difference Cesium-131 internal radiation therapy is making in treating prostate and hard to treat cancers including brain, lung,...

Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

Record Revenue and Gross Profit Revenue Increased 50% Year-Over-Year RICHLAND, WASHINGTON – May 12, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body,...
When is a change worth the trouble for brachytherapy?

When is a change worth the trouble for brachytherapy?

Gains in engagement, conformal coverage, seamless logistics, planning, and procedural efficiency drive Wisconsin brachytherapy program’s transition to Cesium Blu™. “If it ain’t broke, don’t fix it.” The ageless axiom holds true in so many circumstances that it will...
The Big Reason Why One Team Switched to Cesium Blu Brachytherapy

The Big Reason Why One Team Switched to Cesium Blu Brachytherapy

 “The potential to smooth out our workflow and increase our potential candidate pool for the procedure given the ability to do brachytherapy with Cesium Blu prior to EBRT is a compelling motivation for adding it to our prostate cancer treatment arsenal,”- Dr. Bobby...